HOME >> BIOLOGY >> NEWS
Immune Response To Hepatitis B Spares Liver Cells

A new study suggests that, contrary to current belief, the immune system eliminates most hepatitis B virus (HBV) without resorting to large-scale destruction of infected liver cells. A report of the study, conducted by National Institute of Allergy and Infectious Diseases (NIAID) grantees and scientists, appears in the April 30, 1999, issue of Science.

"This is an intriguing finding," notes NIAID Director Anthony S. Fauci, M.D. "By advancing our understanding of how HBV is cleared from the liver, it could lead to better treatments for HBV infection. It also sheds light on how the body protects against spread of an ongoing infection without destroying vital organs."

Scientists have thought that cell-killing T cells bring hepatitis B virus infections to an end by destroying infected liver cells. The current study, however, points to a noncytolytic process that targets the virus' ability to reproduce and leaves the liver relatively unscathed.

Luca G. Guidotti, D.V.M., Ph.D., and Francis V. Chisari, M.D., of the Scripps Research Institute in La Jolla, Calif., led the study, in collaboration with Robert H. Purcell, M.D., chief of NIAID's hepatitis viruses section, and other scientists. The researchers infected two healthy chimpanzees with HBV, then performed weekly blood and liver tests on the animals throughout the course of the infection.

The chimp HBV infections ran their course and the animals recovered without further complications. Most HBV infections in adult humans are similarly uncomplicated. However, between 5 and 10 percent of the estimated 320,000 new HBV infections in the United States each year become persistent, chronic infections. Annually, chronic HBV infection kills as many as 6,000 people in this country.

The researchers found the amount of hepatitis B virus DNA in the chimps' blood and livers peaked eight weeks after infection. The HBV DNA levels then rapidly decreased - by week 12 more than 90 percent of the HBV DNA
'"/>

Contact: John Bowersox
jbowersox@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
30-Apr-1999


Page: 1 2

Related biology news :

1. Immune systems attack dogs kept on genetic leash
2. Immune system drug may increase availability of liver transplants
3. Immune cells may help deliver cancer vaccines for children
4. Immune response depends on key molecule: Research
5. Applied Biosystems and Immune Tolerance Network announce immunology research agreement
6. Immune system component found common to both humans and worms
7. Immune cells SLAP internal signals together
8. Immune co-stimulation and the Kaposis virus
9. Immune system helps prevent tumors after all
10. Even the Immune System works with Pincers
11. Immune system chemical may predict worsening of coronary heart disease in women

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Immune Response Hepatitis Spares Liver Cells

(Date:7/23/2014)... The drought that has the entire country in its grip ... may also be responsible for the proliferation of a heat-loving ... rivers and hot springs, which the drought has made warmer ... died of an infection caused by this parasite after swimming ... the nose of an individual and travels to the brain. ...
(Date:7/23/2014)... available in German . ... cells, drive metabolic processes and transmit signals. To perform ... Scientists at the Max Planck Institute for Developmental Biology ... constructed of similar amino acid chains even when their ... that exist today arose from common precursors. Presumably, in ...
(Date:7/23/2014)... 2014 BioCatch, the global leader ... it has been named in Gartner,s Market Guide for ... Gartner,s well-known Magic Quadrant for Web Fraud Detection. ... of several vendors to deliver passive biometric analysis and ... standard feature of at least 30% of one-stop fraud ...
Breaking Biology News(10 mins):Diseases of another kind 2Protein evolution follows a modular principle 2BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 2BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 3
(Date:7/23/2014)... July 23, 2014 ... of Trendlines Agtech , announced it has ... Israel,s leading agricultural thermoplastics applications companies. ... Valentis,s technology combines nanocrystalline cellulose (NCC), a biodegradable, ... additional nanoparticles to produce highly improved polymeric films. ...
(Date:7/23/2014)... BRUSSELS , July 23, 2014 regulated ... its research and development pipeline with positive topline ... brivaracetam . This study was designed to evaluate ... (100 and 200 mg/day, without titration) compared to ... patients with partial-onset seizures, not fully controlled despite ...
(Date:7/23/2014)... Calif. , July 23, 2014  Sofinnova Ventures, ... firm, today announced the closing of Sofinnova Venture Partners ... and in excess of the initial fund target of ... entrepreneurs build successful biotechnology companies. Consistent with recent funds, ... promising later stage clinical programs, along with select investments ...
(Date:7/23/2014)... 23, 2014 OncLive® is pleased ... has joined its Strategic Alliance Partnership program. ... program, UNC Lineberger will have the opportunity to ... of its cutting-edge research initiatives, community-directed cancer prevention ... will work with OncLive to educate their peers ...
Breaking Biology Technology:Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7Sofinnova Raises $500 Million Biotech Venture Fund 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 3
Cached News: